Biotech Values

[dewophile]

one caveat that should be noted:

the positive control arm is not blinded (would be tough to blind an injectable drug with an oral drug). so the open-label nature of the study might render "superiority" claims subject to scrutiny. This is not to say my enthusiasm is diminished in any way, jsut thought I woudl point this out. what is crystal clear is that the dose-dependent nature of the efficacy response, coupled with the tremendous efficacy signal compared to (albeit an unblinded) positive control gives proellex a fantastic likelihood of success in phase III. this would be a first in class for this indication, and medical toc for endo given po vs im, better side effect profile, etc. congrats rprx holders..personal thanks to rfj for introducing me to this company
PS the market cap is still not even 70M..?!